Report of the forth Asian Prostate Cancer (A-CaP) study meeting

Abstract

The Asian Prostate Cancer (A-CaP) Study is an Asia-wide prospective registry study for surveying the treatment outcome of prostate cancer patients who have received a histopathological diagnosis. The study aims to clarify the clinical situation for prostate cancer in Asia and use the outcomes for the purposes of international comparison. Following the first meeting in Tokyo on December 2015, the second meeting in Seoul, Korea 2016, the third meeting in Chiang Mai, Thailand, on October 2017, the fourth meeting was held in Seoul, again on August 2018 with the participation of members and collaborators from 13 countries and regions. In the meeting, participating countries and regions presented the current status of data collection and the A-CaP office presented a preliminary analysis of the registered cases received from each country and region. Participants discussed ongoing challenges relating to data cleaning and data updating which is the next step of the A-CaP study following the data collection phase between 2016 and 2018. There was specific difference in term of the patient characteristics, and initial treatment pattern among East Asia, Southeast Asia and Turkey, and Jordan. Finally, a close relationship between prevalence of PSA test and disease stage of the patients at diagnosis in Japan and Malaysia was discussed.

United in Fight against prOstate cancer (UFO) registry: first results from a large, multi‐centre, prospective, longitudinal cohort study of advanced prostate cancer in Asia

“…These differences may reflect local practices and guidelines or drug/procedure availability and national reimbursement schemes. The heterogeneity between different countries in Asia is also highlighted by the Asian Prostate Cancer study, which is collecting information on patients with all stages of prostate cancer in Asia .…”

Consensus on safety management of novel hormonal therapy for advanced prostate cancer

“…(3) selecting appropriate drug treatment (e.g., magnesium isoglycyrrhizinate, silymarin, etc.) based on the clinical type of drug-induced liver injury [101] ; (4) if liver injury-related AEs improve to grade 1 or return to the pre-existing grade before the administration of NHT, the NHT can be resumed at either the original dose or a reduced dose; (5) in case of occurrence of grade ≥3 AEs or intolerable AEs when the dose is reduced, the treatment should be permanently discontinued [14,15] . Dose adjustments for the administration of NHT in patients with hepatic and renal dysfunction are variable and are outlined in Table 15.…”

Prostate cancer in multi‐ethnic Asian men: Real‐world experience in the Malaysia Prostate Cancer (M‐CaP) Study

“…Therefore, the Asian Prostate Cancer (A‐CaP) Study was initiated as a multicentre, longitudinal prospective cohort study in 2016 involving 12 Asian nations. The registry includes real‐world data from men with newly diagnosed prostate cancer between 2016 and 2018 in Japan, South Korea, China, Singapore, Malaysia, Thailand, Indonesia, Hong Kong, Taiwan, Turkey, Philippines and Vietnam 6‐9 . The Malaysia Prostate Cancer (M‐CaP) Study Group is one of the key partners in the A‐CaP Study, aiming to evaluate the clinical and tumour characteristics, treatment patterns and survival of prostate cancer patients.…”

“…The registry includes real‐world data from men with newly diagnosed prostate cancer between 2016 and 2018 in Japan, South Korea, China, Singapore, Malaysia, Thailand, Indonesia, Hong Kong, Taiwan, Turkey, Philippines and Vietnam. 6 , 7 , 8 , 9 The Malaysia Prostate Cancer (M‐CaP) Study Group is one of the key partners in the A‐CaP Study, aiming to evaluate the clinical and tumour characteristics, treatment patterns and survival of prostate cancer patients. Here, we describe an overview of the M‐CaP Study Group and present the baseline disease characteristics, treatment profiles as well as outcome of prostate cancer in multiethnic Southeast Asian men.…”